secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2022-12-05T23:59:59+00:00
Accession:  0000950170-22-026020
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta: 70% CR at higher NKX019 doses in NHL; no neurotoxicity observed
-----------------------------------------------------------------------

- 7 of 10 NHL patients at 1B and 1.5B cell doses achieved complete response (70% CR, 80% ORR) across histologies including LBCL.
- No dose-limiting toxicity, ICANS, GvHD, or >Gr3 CRS; safety profile supports outpatient administration.
- Durable responses >6 months seen; 5 CRs after one cycle, 3 partial responses deepened to CR with additional cycles.
- Dose expansion open: monotherapy in LBCL (CAR T naive/experienced) and combination with rituximab.
- Conference call held Dec 5, 2022; NKX019 is an off-the-shelf allogeneic CAR-NK therapy targeting CD19.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022026020/0000950170-22-026020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022026020/nktx-20221205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer